

External Quality Assessment Scheme

SARS-CoV-2, antibodies Round 1, 2023

Specimens

Please find enclosed 3 human plasma or serum samples S001, S002 and S003, each 0.5 mL.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases. The specimens have not been inactivated.

Examinations

SARS-CoV-2 POCT
SARS-CoV-2 total antibodies
SARS-CoV-2 IgG
SARS-CoV-2 IgM
SARS-CoV-2 IgA
Clinical interpretation

When possible, please report the results in BAU/mL.

Storage and use

After arrival, the samples should be stored at +2...8 °C, and used as soon as possible, preferably within a week. The samples are ready for use. Analyse as patient samples.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your test from the registry, please contact the EQA Coordinator. In this round, it is possible to report three results from the same sample, if the sample volume is sufficient for several analyses. To open a new result form, press the "Add result +" button on the right side of the blue bar for each sample in LabScala. All reported examinations will be scored.

S001



S002



S003



2023-01-24

INSTRUCTIONS

Product no. 5677
LQ775823011-013/FI
UN3373

Subcontracting: Sample pretesting

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi.

The results should be reported no later than **February 20, 2023.**

The expected results of the round are published in LabScala in the View Reports section by February 24, 2023.

Inquiries

EQA Coordinator
Marsa Järvenpää
marsa.jarvenpaa@labquality.fi

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



Client report

	No of participants	No of responded participants	Response percentage
SARS-CoV-2, antibodies, January, 1-2023	73	68	93.2 %

Summary




Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Sample S001	4	4	100 %	6.6 %	93.4 %
Sample S002	4	4	100 %	4.1 %	95.9 %
Sample S003	2	2	100 %	2.1 %	97.9 %
Average:			100 %	4.2 %	95.8 %

History	Test nr.	Own success rate	Difference	AVR success rate
Round 2021-4	1-1	100 %	2.7 %	97.3 %
Round 2021-3	1-1	100 %	3.5 %	96.5 %
Round 2021-2	1-1	83.3 %	-4.6 %	87.9 %
Round 2021-2	1-2	100 %	12.1 %	87.9 %
Round 2021-1	1-1	100 %	2.4 %	97.6 %


Sample S001

Sample S001 success rate



Sample S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	-	-	-	-	-	83
	SARS-CoV-2 IgG POC	-	-	-	-	100 %	3
	SARS-CoV-2 IgM POC	-	-	-	-	-	2
	SARS-CoV-2 Ab	-	-	-	-	91.7 %	24
	SARS-CoV-2 IgG	2	2	100 %	1.6 %	98.4 %	64
	SARS-CoV-2 IgM	2	2	100 %	16 %	84 %	25
	SARS-CoV-2 IgA	-	-	-	-	83.3 %	6
	Total:	4	4	100 %	6.6 %	93.4 %	207

Sample S001 Clinical interpretation



Clinical interpretation	Interpretation	Interpretation count	Own score	Max score	Own success rate	Difference	AVR success rate
	Acute/recent infection	14	-	-	-	-	-
	Total antibodies detectable	14	-	-	-	-	-
	Past infection	14	-	-	-	-	-
	Vaccinated	1	-	-	-	-	-
	No detectable antibodies	2	-	-	-	-	-
	Ⓒ Laboratory does not give clinical interpretation	38	-	-	-	-	-
	Total:	83	-	-	-	-	-

Sample S001 SARS-CoV-2 IgG POC



Positive

Sample S001 SARS-CoV-2 IgM POC



Positive

Sample S001 SARS-CoV-2 Ab




Negative Positive

Sample S001 SARS-CoV-2 IgG




Negative Positive

Sample S001 SARS-CoV-2 IgM



Negative Positive

Sample S001 SARS-CoV-2 IgA



Negative Positive

SARS-CoV-2 IgG POC	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		3		-				100 %
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1					
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1					
		Roche SARS-CoV-2 Rapid Antibody Test		1					
	Total:		3		-	-	-	-	100 %

SARS-CoV-2 IgM POC	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate

	Positive		2		-				-
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1					
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1					
	Total:		2		-	-	-	-	

SARS-CoV-2 Ab	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		2		-				0 %
		Roche Elecsys Anti-SARS-CoV-2		1					
		Siemens Atellica SARS-CoV-2 Total Assay		1					
	Positive		22		-				100 %
		Beijing Wantai SARS-CoV-2 Ab ELISA		1					
		Euroimmun SARS-CoV-2 NeutralISA		1					
		Roche Elecsys Anti-SARS-CoV-2		10					
		Roche Elecsys Anti-SARS-CoV-2 S		9					
		Siemens ADVIA Centaur SARS-CoV-2 Total (COV2T)		1					
	Total:		24		-	-	-	-	91.7 %

SARS-CoV-2 IgG	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		Siemens Atellica SARS-COV-2 IgG		1					
	<input checked="" type="radio"/> Positive		63		2	2	100 %	0 %	100 %
		<input checked="" type="radio"/> Abbott Alinity i SARS-CoV-2 IgG		11					
		Abbott Alinity i SARS-CoV-2 IgG II Quant		11					
		Abbott ARCHITECT SARS-CoV-2 IgG II Quant		6					
		bioMérieux VIDAS SARS-CoV-2 IgG		5					
		DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay		8					
		DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG		3					
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgG ELISA		1					
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgG		1					
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG)		1					
		EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG)		2					
		EUROIMMUN Coronavirus Profile EUROLINE (IgG)		1					
		Siemens Advia Centaur SARS-CoV2 IgG		2					
		Siemens Atellica SARS-COV-2 IgG		3					
		Snibe MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA)		3					
		TestLine CLIA COVID-19 RBD IgG		1					
		TestLine EIA COVID-19 RBD IgG		1					
		TestLine Microblot-Array COVID-19 IgG		1					
		Vircell COVID-19 VIRCLIA IgG MONOTEST		2					
	Total:		64		2	2	100 %	1.6 %	98.4 %


SARS-CoV-2 IgM	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		4		-				0 %
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgM ELISA		1					
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgM)		1					
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		2					
	<input checked="" type="radio"/> Positive		21		2	2	100 %	0 %	100 %
		<input checked="" type="radio"/> Abbott Alinity i SARS-CoV-2 IgM		8					
		Abbott ARCHITECT SARS-CoV-2 IgM		2					
		bioMérieux VIDAS SARS-CoV-2 IgM		2					

		DiaSorin LIAISON SARS-CoV-2 IgM		4					
		Snibe MAGLUMI 2019-nCoV IgM		2					
		TestLine CLIA COVID-19 RBD IgM		1					
		TestLine EIA COVID-19 RBD IgM		1					
		TestLine Microblot-Array COVID-19 IgM		1					
	Total:		25		2	2	100 %	16 %	84 %

SARS-CoV-2 IgA	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		1					
	Positive		5		-				100 %
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgA		2					
		TestLine CLIA COVID-19 RBD IgA		1					
		TestLine EIA COVID-19 RBD IgA		1					
		TestLine Microblot-Array COVID-19 IgA		1					
	Total:		6		-	-	-	-	83.3 %


Sample S002

Sample S002 success rate



Sample S002 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	-	-	-	-	93.8 %	83
	SARS-CoV-2 IgG POC	-	-	-	-	100 %	3
	SARS-CoV-2 IgM POC	-	-	-	-	-	2
	SARS-CoV-2 Ab	-	-	-	-	91.7 %	24
	SARS-CoV-2 IgG	2	2	100 %	1.6 %	98.4 %	64
	SARS-CoV-2 IgM	2	2	100 %	0 %	100 %	25
	SARS-CoV-2 IgA	-	-	-	-	100 %	6
	Total:	4	4	100 %	4.1 %	95.9 %	207

Sample S002 Clinical interpretation




Clinical interpretation	Interpretation	Interpretation count	Own score	Max score	Own success rate	Difference	AVR success rate
	No detectable antibodies	45	-	-	-	-	100 %
	Total antibodies detectable	2	-	-	-	-	0 %
	Acute/recent infection	1	-	-	-	-	0 %
	Ⓒ Laboratory does not give clinical interpretation	35	-	-	-	-	-
	Total:	83	-	-	-	-	93.8 %

Sample S002 SARS-CoV-2 IgG POC



■ Negative

Sample S002 SARS-CoV-2 IgM POC




■ Negative

Sample S002 SARS-CoV-2 Ab



■ Negative ■ Positive

Sample S002 SARS-CoV-2 IgG



■ Negative ■ Positive

Sample S002 SARS-CoV-2 IgM



■ Negative

Sample S002 SARS-CoV-2 IgA



■ Negative

SARS-CoV-2 IgG POC	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		3		-				100 %
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1					
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1					
		Roche SARS-CoV-2 Rapid Antibody Test		1					
	Total:		3		-	-	-	-	100 %

SARS-CoV-2 IgM POC	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate

	Negative		2		-				-
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1					
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1					
	Total:		2		-	-	-	-	

SARS-CoV-2 Ab	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		22		-				100 %
		Beijing Wantai SARS-CoV-2 Ab ELISA		1					
		Euroimmun SARS-CoV-2 NeutralISA		1					
		Roche Elecsys Anti-SARS-CoV-2		9					
		Roche Elecsys Anti-SARS-CoV-2 S		10					
		Siemens ADVIA Centaur SARS-CoV-2 Total (COV2T)		1					
	Positive		2		-				0 %
		Roche Elecsys Anti-SARS-CoV-2		1					
		Siemens Atellica SARS-CoV-2 Total Assay		1					
	Total:		24		-	-	-	-	91.7 %

SARS-CoV-2 IgG	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		63		2	2	100 %	0 %	100 %
		<input checked="" type="radio"/> Abbott Alinity i SARS-CoV-2 IgG		11					
		Abbott Alinity i SARS-CoV-2 IgG II Quant		13					
		Abbott ARCHITECT SARS-CoV-2 IgG II Quant		4					
		bioMérieux VIDAS SARS-CoV-2 IgG		5					
		DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay		8					
		DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG		3					
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgG ELISA		1					
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgG		1					
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG)		1					
		EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG)		2					
		EUROIMMUN Coronavirus Profile EUROLINE (IgG)		1					
		Siemens Advia Centaur SARS-CoV2 IgG		2					
		Siemens Atellica SARS-COV-2 IgG		3					
		Snibe MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA)		3					
		TestLine CLIA COVID-19 RBD IgG		1					
		TestLine EIA COVID-19 RBD IgG		1					
		TestLine Microblot-Array COVID-19 IgG		1					
		Vircell COVID-19 VIRCLIA IgG MONOTEST		2					
	Positive		1		-				0 %
		Siemens Atellica SARS-COV-2 IgG		1					
	Total:		64		2	2	100 %	1.6 %	98.4 %


SARS-CoV-2 IgM	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		25		2	2	100 %	0 %	100 %
		<input checked="" type="radio"/> Abbott Alinity i SARS-CoV-2 IgM		9					
		Abbott ARCHITECT SARS-CoV-2 IgM		1					
		bioMérieux VIDAS SARS-CoV-2 IgM		2					
		DiaSorin LIAISON SARS-CoV-2 IgM		4					
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgM ELISA		1					
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgM)		1					
		Snibe MAGLUMI 2019-nCoV IgM		2					

		TestLine CLIA COVID-19 RBD IgM		1					
		TestLine EIA COVID-19 RBD IgM		1					
		TestLine Microblot-Array COVID-19 IgM		1					
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		2					
	Total:		25		2	2	100 %	0 %	100 %

SARS-CoV-2 IgA	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		6		-				100 %
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgA		2					
		TestLine CLIA COVID-19 RBD IgA		1					
		TestLine EIA COVID-19 RBD IgA		1					
		TestLine Microblot-Array COVID-19 IgA		1					
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		1					
	Total:		6		-	-	-	-	100 %


Sample S003

Sample S003 success rate



Sample S003 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	-	-	-	-	-	83
	SARS-CoV-2 IgG POC	-	-	-	-	100 %	3
	SARS-CoV-2 IgM POC	-	-	-	-	-	2
	SARS-CoV-2 Ab	-	-	-	-	95.8 %	24
	SARS-CoV-2 IgG	2	2	100 %	0 %	100 %	64
	SARS-CoV-2 IgM	-	-	-	-	-	25
	SARS-CoV-2 IgA	-	-	-	-	83.3 %	6
	Total:	2	2	100 %	2.1 %	97.9 %	207

Sample S003 Clinical interpretation



Clinical interpretation	Interpretation	Interpretation count	Own score	Max score	Own success rate	Difference	AVR success rate
	Acute/recent infection	11	-	-	-	-	-
	Total antibodies detectable	15	-	-	-	-	-
	Past infection	17	-	-	-	-	-
	Vaccinated	2	-	-	-	-	-
	⊙ Laboratory does not give clinical interpretation	38	-	-	-	-	-
	Total:	83	-	-	-	-	-

Sample S003 SARS-CoV-2 IgG POC




Positive

Sample S003 SARS-CoV-2 IgM POC



Positive

Sample S003 SARS-CoV-2 Ab



Negative Borderline Positive

Sample S003 SARS-CoV-2 IgG




Positive

Sample S003 SARS-CoV-2 IgM



Negative Positive

Sample S003 SARS-CoV-2 IgA



Negative Positive

SARS-CoV-2 IgG POC	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		3		-				100 %
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1					
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1					
		Roche SARS-CoV-2 Rapid Antibody Test		1					
	Total:		3		-	-	-	-	100 %

SARS-CoV-2 IgM POC	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate

	Positive		2		-				-
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1					
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1					
	Total:		2		-	-	-	-	

SARS-CoV-2 Ab	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		Roche Elecsys Anti-SARS-CoV-2 S		1					
	Borderline		1		-				100 %
		Euroimmun SARS-CoV-2 NeutralISA		1					
	Positive		22		-				100 %
		Beijing Wantai SARS-CoV-2 Ab ELISA		1					
		Roche Elecsys Anti-SARS-CoV-2		10					
		Roche Elecsys Anti-SARS-CoV-2 S		9					
		Siemens ADVIA Centaur SARS-CoV-2 Total (COV2T)		1					
		Siemens Atellica SARS-CoV-2 Total Assay		1					
	Total:		24		-	-	-	-	95.8 %

SARS-CoV-2 IgG	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		64		2	2	100 %	0 %	100 %
		<input checked="" type="radio"/> Abbott Alinity i SARS-CoV-2 IgG		11					
		Abbott Alinity i SARS-CoV-2 IgG II Quant		13					
		Abbott ARCHITECT SARS-CoV-2 IgG II Quant		4					
		bioMérieux VIDAS SARS-CoV-2 IgG		5					
		DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay		8					
		DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG		3					
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgG ELISA		1					
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgG		1					
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG)		1					
		EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG)		2					
		EUROIMMUN Coronavirus Profile EUROLINE (IgG)		1					
		Siemens Advia Centaur SARS-CoV2 IgG		2					
		Siemens Atellica SARS-COV-2 IgG		4					
		Snibe MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA)		3					
		TestLine CLIA COVID-19 RBD IgG		1					
		TestLine EIA COVID-19 RBD IgG		1					
		TestLine Microblot-Array COVID-19 IgG		1					
		Vircell COVID-19 VIRCLIA IgG MONOTEST		2					
	Total:		64		2	2	100 %	0 %	100 %

SARS-CoV-2 IgM	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		14		-				-
		bioMérieux VIDAS SARS-CoV-2 IgM		2					
		DiaSorin LIAISON SARS-CoV-2 IgM		3					
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgM ELISA		1					
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgM)		1					
		Snibe MAGLUMI 2019-nCoV IgM		2					
		TestLine CLIA COVID-19 RBD IgM		1					
		TestLine EIA COVID-19 RBD IgM		1					
		TestLine Microblot-Array COVID-19 IgM		1					

		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		2					
	<input checked="" type="radio"/> Positive		11		-				-
		<input checked="" type="radio"/> Abbott Alinity i SARS-CoV-2 IgM		9					
		Abbott ARCHITECT SARS-CoV-2 IgM		1					
		DiaSorin LIAISON SARS-CoV-2 IgM		1					
	Total:		25		-	-	-	-	

SARS-CoV-2 IgA	Interpretation	Test kit	Interpretation count	Test kit count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		1					
	Positive		5		-				100 %
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgA		2					
		TestLine CLIA COVID-19 RBD IgA		1					
		TestLine EIA COVID-19 RBD IgA		1					
		TestLine Microblot-Array COVID-19 IgA		1					
	Total:		6		-	-	-	-	83.3 %

Report Info

PARTICIPANTS

Altogether 73 laboratories from 23 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results when 60% or more of the participants report the expected result and when at least three results are reported. The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
SARS-CoV-2, antibodies, January, 1-2023	73	68	93.2 %


Summary



Summary	AVR success rate
Sample S001	93.4 %
Sample S002	95.9 %
Sample S003	97.9 %
Average:	95.8 %


Sample S001

Sample S001 success rate




Sample S001 results	Responded	AVR success rate	Count
	Clinical interpretation	-	83
	SARS-CoV-2 IgG POC	100 %	3
	SARS-CoV-2 IgM POC	-	2
	SARS-CoV-2 Ab	91.7 %	24
	SARS-CoV-2 IgG	98.4 %	64
	SARS-CoV-2 IgM	84 %	25
	SARS-CoV-2 IgA	83.3 %	6
	Total:	93.4 %	207

Sample S001 Clinical interpretation




Clinical interpretation	Interpretation	Interpretation count	AVR success rate	Interpretation Score
	Acute/recent infection	14	-	-
	Total antibodies detectable	14	-	-
	Past infection	14	-	-
	Vaccinated	1	-	-
	No detectable antibodies	2	-	-
	Laboratory does not give clinical interpretation	38	-	-
	Total:	83		

Sample S001 SARS-CoV-2 IgG POC



Positive

Sample S001 SARS-CoV-2 IgM POC



Positive

Sample S001 SARS-CoV-2 Ab




Negative Positive

Sample S001 SARS-CoV-2 IgG




Negative Positive

Sample S001 SARS-CoV-2 IgM



Negative Positive

Sample S001 SARS-CoV-2 IgA



Negative Positive

SARS-CoV-2 IgG POC	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Positive		3		100 %	2
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1		
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1		
		Roche SARS-CoV-2 Rapid Antibody Test		1		
	Total:		3		100 %	

SARS-CoV-2 IgM POC	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Positive		2		-	-

		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1		
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1		
	Total:			2		

SARS-CoV-2 Ab	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		2		0 %	0
		Roche Elecsys Anti-SARS-CoV-2		1		
		Siemens Atellica SARS-CoV-2 Total Assay		1		
	Positive		22		100 %	2
		Beijing Wantai SARS-CoV-2 Ab ELISA		1		
		Euroimmun SARS-CoV-2 NeutraLISA		1		
		Roche Elecsys Anti-SARS-CoV-2		10		
		Roche Elecsys Anti-SARS-CoV-2 S		9		
		Siemens ADVIA Centaur SARS-CoV-2 Total (COV2T)		1		
	Total:		24		91.7 %	

SARS-CoV-2 IgG	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		1		0 %	0
		Siemens Atellica SARS-COV-2 IgG		1		
	Positive		63		100 %	2
		Abbott Alinity i SARS-CoV-2 IgG		11		
		Abbott Alinity i SARS-CoV-2 IgG II Quant		11		
		Abbott ARCHITECT SARS-CoV-2 IgG II Quant		6		
		bioMérieux VIDAS SARS-CoV-2 IgG		5		
		DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay		8		
		DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG		3		
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgG ELISA		1		
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgG		1		
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG)		1		
		EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG)		2		
		EUROIMMUN Coronavirus Profile EUROLINE (IgG)		1		
		Siemens Advia Centaur SARS-CoV2 IgG		2		
		Siemens Atellica SARS-COV-2 IgG		3		
		Snibe MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA)		3		
		TestLine CLIA COVID-19 RBD IgG		1		
		TestLine EIA COVID-19 RBD IgG		1		
		TestLine Microblot-Array COVID-19 IgG		1		
		Vircell COVID-19 VIRCLIA IgG MONOTEST		2		
	Total:		64		98.4 %	


SARS-CoV-2 IgM	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		4		0 %	0
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgM ELISA		1		
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgM)		1		
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		2		
	Positive		21		100 %	2
		Abbott Alinity i SARS-CoV-2 IgM		8		
		Abbott ARCHITECT SARS-CoV-2 IgM		2		
		bioMérieux VIDAS SARS-CoV-2 IgM		2		
		DiaSorin LIAISON SARS-CoV-2 IgM		4		
		Snibe MAGLUMI 2019-nCoV IgM		2		
		TestLine CLIA COVID-19 RBD IgM		1		
		TestLine EIA COVID-19 RBD IgM		1		
		TestLine Microblot-Array COVID-19 IgM		1		
	Total:		25		84 %	

SARS-CoV-2 IgA	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		1		0 %	0

		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		1		
	Positive		5		100 %	2
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgA		2		
		TestLine CLIA COVID-19 RBD IgA		1		
		TestLine EIA COVID-19 RBD IgA		1		
		TestLine Microblot-Array COVID-19 IgA		1		
	Total:		6		83.3 %	


Sample S002

Sample S002 success rate




Sample S002 results	Responded	AVR success rate	Count
	Clinical interpretation	93.8 %	83
	SARS-CoV-2 IgG POC	100 %	3
	SARS-CoV-2 IgM POC	-	2
	SARS-CoV-2 Ab	91.7 %	24
	SARS-CoV-2 IgG	98.4 %	64
	SARS-CoV-2 IgM	100 %	25
	SARS-CoV-2 IgA	100 %	6
	Total:	95.9 %	207

Sample S002 Clinical interpretation




Clinical interpretation	Interpretation	Interpretation count	AVR success rate	Interpretation Score
	No detectable antibodies	45	100 %	4
	Total antibodies detectable	2	0 %	0
	Acute/recent infection	1	0 %	0
	Laboratory does not give clinical interpretation	35	-	-
	Total:	83	93.8 %	


Sample S002 SARS-CoV-2 IgG POC




Sample S002 SARS-CoV-2 IgM POC




Sample S002 SARS-CoV-2 Ab




Sample S002 SARS-CoV-2 IgG



Sample S002 SARS-CoV-2 IgM



Sample S002 SARS-CoV-2 IgA



SARS-CoV-2 IgG POC	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		3		100 %	2
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1		
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1		
		Roche SARS-CoV-2 Rapid Antibody Test		1		
	Total:		3		100 %	

SARS-CoV-2 IgM POC	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		2		-	-

		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1		
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1		
	Total:			2		

SARS-CoV-2 Ab	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		22		100 %	2
		Beijing Wantai SARS-CoV-2 Ab ELISA		1		
		Euroimmun SARS-CoV-2 NeutraLISA		1		
		Roche Elecsys Anti-SARS-CoV-2		9		
		Roche Elecsys Anti-SARS-CoV-2 S		10		
		Siemens ADVIA Centaur SARS-CoV-2 Total (COV2T)		1		
	Positive		2		0 %	0
		Roche Elecsys Anti-SARS-CoV-2		1		
		Siemens Atellica SARS-CoV-2 Total Assay		1		
	Total:		24		91.7 %	

SARS-CoV-2 IgG	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		63		100 %	2
		Abbott Alinity i SARS-CoV-2 IgG		11		
		Abbott Alinity i SARS-CoV-2 IgG II Quant		13		
		Abbott ARCHITECT SARS-CoV-2 IgG II Quant		4		
		bioMérieux VIDAS SARS-CoV-2 IgG		5		
		DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay		8		
		DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG		3		
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgG ELISA		1		
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgG		1		
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG)		1		
		EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG)		2		
		EUROIMMUN Coronavirus Profile EUROLINE (IgG)		1		
		Siemens Advia Centaur SARS-CoV2 IgG		2		
		Siemens Atellica SARS-COV-2 IgG		3		
		Snibe MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA)		3		
		TestLine CLIA COVID-19 RBD IgG		1		
		TestLine EIA COVID-19 RBD IgG		1		
		TestLine Microblot-Array COVID-19 IgG		1		
		Vircell COVID-19 VIRCLIA IgG MONOTEST		2		
	Positive		1		0 %	0
		Siemens Atellica SARS-COV-2 IgG		1		
	Total:		64		98.4 %	


SARS-CoV-2 IgM	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		25		100 %	2
		Abbott Alinity i SARS-CoV-2 IgM		9		
		Abbott ARCHITECT SARS-CoV-2 IgM		1		
		bioMérieux VIDAS SARS-CoV-2 IgM		2		
		DiaSorin LIAISON SARS-CoV-2 IgM		4		
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgM ELISA		1		
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgM)		1		
		Snibe MAGLUMI 2019-nCoV IgM		2		
		TestLine CLIA COVID-19 RBD IgM		1		
		TestLine EIA COVID-19 RBD IgM		1		
		TestLine Microblot-Array COVID-19 IgM		1		
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		2		
	Total:		25		100 %	

SARS-CoV-2 IgA	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		6		100 %	2
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgA		2		

		TestLine CLIA COVID-19 RBD IgA		1		
		TestLine EIA COVID-19 RBD IgA		1		
		TestLine Microblot-Array COVID-19 IgA		1		
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		1		
	Total:		6		100 %	


Sample S003

Sample S003 success rate




Sample S003 results	Responded	AVR success rate	Count
	Clinical interpretation	-	83
	SARS-CoV-2 IgG POC	100 %	3
	SARS-CoV-2 IgM POC	-	2
	SARS-CoV-2 Ab	95.8 %	24
	SARS-CoV-2 IgG	100 %	64
	SARS-CoV-2 IgM	-	25
	SARS-CoV-2 IgA	83.3 %	6
	Total:	97.9 %	207

Sample S003 Clinical interpretation




Clinical interpretation	Interpretation	Interpretation count	AVR success rate	Interpretation Score
	Acute/recent infection	11	-	-
	Total antibodies detectable	15	-	-
	Past infection	17	-	-
	Vaccinated	2	-	-
	Laboratory does not give clinical interpretation	38	-	-
	Total:	83		

Sample S003 SARS-CoV-2 IgG POC




Positive

Sample S003 SARS-CoV-2 IgM POC



Positive

Sample S003 SARS-CoV-2 Ab



Negative Borderline Positive

Sample S003 SARS-CoV-2 IgG




Positive

Sample S003 SARS-CoV-2 IgM



Negative Positive

Sample S003 SARS-CoV-2 IgA



Negative Positive

SARS-CoV-2 IgG POC	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Positive		3		100 %	2
		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1		
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1		
		Roche SARS-CoV-2 Rapid Antibody Test		1		
	Total:		3		100 %	

SARS-CoV-2 IgM POC	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Positive		2		-	-

		Hangzhou Singclean COVID-19 IgG/IgM Test Kit (Colloidal Gold Method)		1		
		nal von minden NADAL COVID-19 IgG/IgM Rapid Test		1		
	Total:			2		

SARS-CoV-2 Ab	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		1		0 %	0
		Roche Elecsys Anti-SARS-CoV-2 S		1		
	Borderline		1		100 %	2
		Euroimmun SARS-CoV-2 NeutralISA		1		
	Positive		22		100 %	2
		Beijing Wantai SARS-CoV-2 Ab ELISA		1		
		Roche Elecsys Anti-SARS-CoV-2		10		
		Roche Elecsys Anti-SARS-CoV-2 S		9		
		Siemens ADVIA Centaur SARS-CoV-2 Total (COV2T)		1		
		Siemens Atellica SARS-CoV-2 Total Assay		1		
	Total:		24		95.8 %	

SARS-CoV-2 IgG	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Positive		64		100 %	2
		Abbott Alinity i SARS-CoV-2 IgG		11		
		Abbott Alinity i SARS-CoV-2 IgG II Quant		13		
		Abbott ARCHITECT SARS-CoV-2 IgG II Quant		4		
		bioMérieux VIDAS SARS-CoV-2 IgG		5		
		DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay		8		
		DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG		3		
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgG ELISA		1		
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgG		1		
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG)		1		
		EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG)		2		
		EUROIMMUN Coronavirus Profile EUROLINE (IgG)		1		
		Siemens Advia Centaur SARS-CoV2 IgG		2		
		Siemens Atellica SARS-COV-2 IgG		4		
		Snibe MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA)		3		
		TestLine CLIA COVID-19 RBD IgG		1		
		TestLine EIA COVID-19 RBD IgG		1		
		TestLine Microblot-Array COVID-19 IgG		1		
		Vircell COVID-19 VIRCLIA IgG MONOTEST		2		
	Total:		64		100 %	

SARS-CoV-2 IgM	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		14		-	-
		bioMérieux VIDAS SARS-CoV-2 IgM		2		
		DiaSorin LIAISON SARS-CoV-2 IgM		3		
		Epitope Diagnostics EDI Novel Coronavirus COVID-19 IgM ELISA		1		
		EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgM)		1		
		Snibe MAGLUMI 2019-nCoV IgM		2		
		TestLine CLIA COVID-19 RBD IgM		1		
		TestLine EIA COVID-19 RBD IgM		1		
		TestLine Microblot-Array COVID-19 IgM		1		
		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		2		
	Positive		11		-	-
		Abbott Alinity i SARS-CoV-2 IgM		9		
		Abbott ARCHITECT SARS-CoV-2 IgM		1		
		DiaSorin LIAISON SARS-CoV-2 IgM		1		
	Total:		25			

SARS-CoV-2 IgA	Interpretation	Test kit	Interpretation count	Test kit count	AVR success rate	Interpretation Score
	Negative		1		0 %	0

		Vircell COVID-19 VIRCLIA IgM+IgA MONOTEST		1		
	Positive		5		100 %	2
		EUROIMMUN Anti-SARS-CoV-2 ELISA IgA		2		
		TestLine CLIA COVID-19 RBD IgA		1		
		TestLine EIA COVID-19 RBD IgA		1		
		TestLine Microblot-Array COVID-19 IgA		1		
	Total:		6		83.3 %	

Report Info

PARTICIPANTS

Altogether 73 laboratories from 23 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results when 60% or more of the participants report the expected result and when at least three results are reported. The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

External Quality Assessment Scheme

SARS-CoV-2, antibodies Round 1, 2023

Specimens

Samples of this EQA round were human plasma or serum, each of which originated from a single donor. The homogeneity of samples was ensured during the sample preparation. The antibodies are known to be stable and there are no special requirements for their handling or storage. The samples were suitable for the external quality assessment scheme. The materials were sent without temperature control packaging.

The expected results were as follows:

Sample S001 (LQ775823011)

SARS-CoV-2 Ab	Positive
SARS-CoV-2 IgG	Positive
SARS-CoV-2 IgM	Positive
SARS-CoV-2 IgA	Positive

Sample S002 (LQ775823012)

SARS-CoV-2 Ab	Negative
SARS-CoV-2 IgG	Negative
SARS-CoV-2 IgM	Negative
SARS-CoV-2 IgA	Negative

Sample S003 (LQ775823013)

SARS-CoV-2 Ab	Positive
SARS-CoV-2 IgG	Positive
SARS-CoV-2 IgM	Borderline/Positive
SARS-CoV-2 IgA	Positive

Pre-test methods: Abbott ARCHITECT SARS-CoV-2 IgG/IgM, DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG, Euroimmun SARS-CoV-2 IgG/IgA and/or In-house Ab/IgG/IgM/IgA.

Report info

Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – Expert

On this EQA round, almost all responders reported total and IgG antibody results correctly. Errors, including false positive results in sample S002 were mostly apparent sample mix-ups. IgM results had more disagreements. Four participants using 3 different methods reported a negative IgM result in samples S001 and S003, whereas 10 users of Abbott Alinity or Architect reported both samples as IgM positive. IgA tests were used by only 6 participants, and 5 of them reported unanimously correct positive results. Virclia IgM+IgA Monotest gave negative results for both IgM and IgA positive samples.

Exceptions in scoring

Clinical interpretations for samples S001 and S003 and IgM test results in sample S003 were not scored.

Annex

Quantitative SARS-CoV-2 IgG results (Annex 1).

2023-03-09

FINAL REPORT

Product no. 5677

Samples sent	2023-01-24
Round closed	2023-02-20
Expected results	2023-02-21
Final report	2023-03-09

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Marsa Järvenpää
marsa.jarvenpaa@labquality.fi

Expert

Docent Matti Waris,
University of Turku, Finland

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



End of report

Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.

Annex 1. Quantitative SARS-CoV-2 IgG results.

Method	S001 SARS-CoV-2 IgG	S003 SARS-CoV-2 IgG
Abbott Alinity i SARS-CoV-2 IgG	4.65 index 5.32 index 5.69 index 5.73 index 5.88 index 5.90 index 6.09 index 6.23 index 6.38 index 5.65 S/CO 7.86 AU/mL	3.97 index 4.72 index 5.07 index 5.09 index 5.21 index 5.25 index 5.40 index 5.63 index 5.12 S/CO 6.96 AU/mL 459.9 AU/mL
Abbott Alinity i SARS-CoV-2 IgG II Quant	599.8 AU/mL 601.3 AU/mL 604.9 AU/mL 631.3 AU/mL 613.7 U/mL 77.3 BAU/mL 79.57 BAU/mL 80.1 BAU/mL 82.43 BAU/mL 85.06 BAU/mL 87.2 BAU/mL - -	417.7 AU/mL 425.0 AU/mL 459 AU/mL 472.3 AU/mL 482.1 AU/mL 452.2 U/mL 58.0 BAU/mL 58.65 BAU/mL 59.50 BAU/mL 59.85 BAU/mL 60.71 BAU/mL 61.4 BAU/mL 63.2 BAU/mL
Abbott ARCHITECT SARS-CoV-2 IgG II Quant	539.2 AU/mL 591.7 AU/mL 633.4 AU/mL 679.6 AU/mL 696.9 AU/mL 86.9 BAU/mL	443.9 AU/mL 448.5 AU/mL 491.0 AU/mL 498.1 AU/mL - -
bioMérieux VIDAS SARS-CoV-2 IgG	5.42 index 5.61 index 6.03 index 97 BAU/mL	3.91 index 4.24 index 4.47 index 73 BAU/mL
DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay	126 BAU/mL 131 BAU/mL 132 BAU/mL 134 BAU/mL 137 BAU/mL 138 BAU/mL 139 BAU/mL 140 BAU/mL	100 BAU/mL 117 BAU/mL 123 BAU/mL 123 BAU/mL 123 BAU/mL 126 BAU/mL 128 BAU/mL 132 BAU/mL
DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG	33.5 AU/mL 35.5 AU/mL 36.2 AU/mL	34.2 AU/mL 38.7 AU/mL 39.9 AU/mL
Epitope Diagnostics EDI Novel Coronavirus COVID-19	13.720 UA/mL	27.750 UA/mL
EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG)	4.6 S/CO	3.7 S/CO
EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG)	121.3 BAU/mL 216 BAU/mL	141 BAU/mL 89 BAU/mL
Siemens Advia Centaur SARS-CoV-2 IgG	1.95 IU/mL 67.14 BAU/mL	1.95 IU/mL 48.4 BAU/mL
Siemens Atellica SARS-COV-2 IgG	<10.9 BAU/mL 81.75 BAU/mL 85.02 BAU/mL 89.16 BAU/mL	63.22 BAU/mL 64.09 BAU/mL 66.99 BAU/mL 68.45 BAU/mL
Snibe MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA)	16.30 AU/mL 56.7 BAU/mL 58.89 BAU/mL	16.10 AU/mL 46.9 BAU/mL 58.89 BAU/mL

TestLine CLIA COVID-19 RBD IgG	172.43 U/mL	148.76 U/mL
TestLine EIA COVID-19 RBD IgG	2.21 index	1.43 index
Vircell COVID-19 VIRCLIA IgG MONOTEST	68.3 IU/mL 9.186 index	61.3 IU/mL 8.124 index